Cyclacel Pharmaceuticals Changes Certifying Accountant
Ticker: BGMSP · Form: 8-K · Filed: Aug 28, 2025 · CIK: 1130166
Sentiment: neutral
Topics: auditor-change, administrative
Related Tickers: CYCC
TL;DR
Cyclacel swapped accountants, filing an 8-K on 8/28/25.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed an 8-K on August 28, 2025, reporting a change in its certifying accountant as of August 22, 2025. The filing also includes financial statements and exhibits. The company was formerly known as XCYTE THERAPIES INC until December 18, 2000.
Why It Matters
A change in auditor can signal potential shifts in financial reporting or internal controls, warranting closer examination by investors.
Risk Assessment
Risk Level: low — This filing primarily concerns administrative changes related to the company's auditors and does not appear to involve significant operational or financial events.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- XCYTE THERAPIES INC (company) — Former company name
- August 22, 2025 (date) — Date of earliest event reported
- August 28, 2025 (date) — Date of report
FAQ
What is the primary reason for the change in Cyclacel Pharmaceuticals' certifying accountant?
The filing states that there was a change in registrant's certifying accountant as of August 22, 2025, but does not provide specific details on the reasons for this change.
When was the change in the certifying accountant effective?
The change in the certifying accountant was effective as of August 22, 2025.
What other information is included in this 8-K filing?
This 8-K filing includes information on the change in registrant's certifying accountant, as well as financial statements and exhibits.
What was Cyclacel Pharmaceuticals, Inc. previously known as?
Cyclacel Pharmaceuticals, Inc. was formerly known as XCYTE THERAPIES INC.
On what date was the company's name changed from XCYTE THERAPIES INC?
The date of the name change from XCYTE THERAPIES INC was December 18, 2000.
Filing Stats: 921 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2025-08-28 06:10:48
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex16-1.htm (EX-16.1) — 6KB
- form8-k_001.jpg (GRAPHIC) — 14KB
- 0001641172-25-025752.txt ( ) — 297KB
- cycc-20250822.xsd (EX-101.SCH) — 4KB
- cycc-20250822_def.xml (EX-101.DEF) — 26KB
- cycc-20250822_lab.xml (EX-101.LAB) — 36KB
- cycc-20250822_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 28, 2025 Cyclacel Pharmaceuticals, Inc. By: /s/ Datuk Dr. Doris Wong Sing Ee Name: Datuk Dr. Doris Wong Sing Ee Title: Chief Executive Officer and Executive Director